EGFR and non-small cell lung carcinoma: Recently, GPX4 was discovered to be associated with resistance to anticancer drugs such as cisplatin, as well as “EGFR tyrosine kinase inhibitors (EGFR-TKIs), in non-small-cell lung cancer (NSCLC)” [9, 12, 13].